Father-Daughter Bond Takes Center Stage In Powerful True Story Of Courage And Undying Love
Fort Wayne, IN, July 1, 2020 — Brittany Moser was a young, happy-go-lucky flight attendant, soaring high above reality, when an incurable disease suddenly brought her down to earth. Rather than buckle under the weight of her fear, she chose to be fearless and embarked upon the adventure of a lifetime with her best friend — her father. Free and Fearless: The Amazing Impact of One Precious Lifeis Brittany’s unforgettable story as told by her father Philip Moser.
“This book is not about the grief of losing a child, but about making the most out of what we are given and living our lives positively and not out of fear,” Moser writes. “Brittany inspired me, an ordinary farm boy, to explore life, to climb mountains and to write a book.”
In 2015, Brittany was diagnosed with Addison’s disease, a rare condition that can lead to adrenal failure. She passed away in 2017.
The book is an honest, poignant account of Brittany’s legacy and the ripple effect that her outlook on life had on those around her. Among Brittany’s valuable life lessons that Philip shares with readers are:
1. How precious life is and how we can affect the people around us; 2. How an open mind and a positive attitude can inspire us to do things we never thought possible; 3. How to move out of our comfort zones and into a challenging existence that can turn each day into an exciting gift to be explored; 4. How to not let fear control us, and to use our abilities to seek unique, positive and inspiring adventures; 5. To embrace change as a natural part of life; 6. And finally, that we won’t be remembered by our things or our savings accounts, but by how we made other people feel.
“I want to share the same inspiration that I received for 32 years,” Philip added. “In the end, love truly does conquer all, and Brittany wanted us to know that.”
Author Philip Moser grew up on a farm in Angola, Indiana. After high school, he began working in different aspects of the grocery business, a career that continues to this day. He and his wife, Marilyn Wells, raised two incredible daughters, Camille and Brittany.
Physician-Created App Unveils Remote Check-In Feature to Prevent Spread of COVID-19 in Medical Practices
TAMPA, FLA. - DocClocker®, a pioneering app that allows patients – for the first time – to receive real-time wait time reporting of their medical providers, has been aggressively preventing the spread of COVID-19 (coronavirus) nationwide by enabling patients to avoid long waits in medical waiting rooms – limiting exposure risks. Today, the company announced their latest achievement in supporting both providers and patients during the pandemic: DocClocker Remote Check-In.
In the wake of COVID-19, healthcare providers are being forced to rethink the traditional waiting room experience. DocClocker, a medical wait time reporting app that was founded and is run entirely by practicing physicians, is taking that step with the launch of DocClocker Remote Check-In. For the first time, patients can now remotely check-in to their doctor appointments from their car, in addition to receiving real-time wait time reporting; preventing the spread of the highly contagious virus by limiting the exposure of sick patients in waiting rooms.
“Recognizing that the waiting room during the COVID-19 pandemic is a potentially risky place to be, the new DocClocker Remote Check-In enables the healthcare system to function while keeping current best practice recommendations to maintain social distancing,” said Dr. Eric Carter, Co-CEO and Co-Founder of DocClocker.
Healthcare organizations across the United States are successfully using DocClocker to improve patient outcomes, prevent the spread of illness, increase new patient appointment bookings, improve practice online reputation and searchability, and much more. DocClocker can be installed and implemented to any healthcare waiting room in America in mere minutes.
In addition to remote check-ins and receiving real-time wait times, patients can easily locate and select in-network medical providers; selecting by reviewing the provider’s specific information and a display of average wait times. Patients can manage appointments through the app, receive appointment reminders, write reviews and report long waits. DocClocker is free to all patients and is significantly more affordable than basic appointment management tools that have dominated the market in recent years.
About DocClocker: Developed by Fast Pathway Inc, DocClocker brings transparency to the doctor’s waiting room using modern technology to streamline communication between doctors, patients, and their families. For more information about DocClocker, please visit the app’s website at: https://docclocker.com/
Location Information: Fast Pathway Inc 2202 North Westshore Blvd., Suite 200 Tampa, Florida 33607
About Fast Pathway, Inc: Fast Pathway Inc is the developer and operator of the DocClocker® platform and maintains the cloud-based technology for subscribers and users.
If you would rather not receive future communications from Jacobson Strategy, let us know by clicking here. Jacobson Strategy, 6304 Vista Verde Drive East, Gulfport, FL 33707 United States
Summer is here, which normally means it’s time to take a vacation! In the age of the Coronavirus Pandemic, many plans are being changed or curtailed. No matter where you’re going, if you’re not prepared, a potentially amazing holiday can turn out to be the worst. Here are our summer health tips to make sure everything goes smoothly and as safely as possible.
Wash your hands regularly
It might seem obvious, but this is your best and easiest way to stay healthy while you're traveling. Regular handwashing can help prevent COVID-19 transmission as well as more routine illnesses like diarrhea and respiratory infections. Washing up can also help you avoid bacteria such as E. coli and salmonella, which can cause major gastrointestinal issues (or even something worse). You’ll also remove germs left from a sneeze or other factors that can cause colds and other illnesses that can ruin your trip.
And consider the health and habits of the people around you. Take antibacterial wipes to deal with germy surfaces, such as a gas pump, door handles, or hotel room surfaces.
Eat and drink in moderation
There’s no shame in indulging when you’re on vacation, but try to keep a balance between occasional splurges and nutritious food. For example, if you're planning a big dinner, try eating light vegetables during the day.
Also, try to eat vegetables at least once daily while traveling. Dark, leafy greens are especially a good choice: They can improve your mood and energy.
To further protect your health, try to eat outdoors whenever possible and avoid smaller, older restaurants. Getting to-go orders is a smart alternative as well and provide the opportunity for a fun family picnic.
Stay hydrated
It can be challenging to drink enough water when you’re busy enjoying the summer and sightseeing. However, dehydration can cause headaches, fatigue and even serious health problems.
Here are some useful tips:
Bring an empty bottle to the airport and fill it at the terminal.
Keep a bottle of water with you everywhere you go — and make sure you bring extra water for any children traveling with you.
Download an app to track your water intake and get notifications.
Get enough sleep
Vacation is a time for both play and rest. If you get less than six hours of sleep per night, even for just a week, you’re more likely to get a common cold than people who sleep more. If your body is thrown off from jet-lag, try taking a melatonin pill on the first night or two in your new environment. This will prepare your body to relax at your new bedtime.
Get some exercise
Even if you need a relaxing vacation where rest is the only thing you've planned, try to get at least 30 minutes of physical activity every day. Exercising on vacation can help you recover from any stiffness from sleeping in a new bed, and it improves your overall energy level. Consider exercising outdoors and avoiding enclosed gyms and studios.
Use your sunscreen
Days spent at the pool or the beach mean more exposure to the sun’s harmful rays. Use a sunscreen with a sun protection factor (SPF) of at least 30 and apply it every couple of hours or when you’re sweaty and/or wet. This will reduce your risk for skin cancer. Hats are great extra protection for you and your kids.
Charcoal a weapon to fight superoxide-induced disease, injury Nanomaterials soak up radicals, could aid treatment of COVID-19
HOUSTON – (July 1, 2020) – Artificial enzymes made of treated charcoal could have the power to curtail damaging levels of superoxides, radical oxygen ions that are toxic at high concentrations.
The nanozymes developed by a Texas Medical Center team are highly effective antioxidants that break down damaging reactive oxygen species (ROS) produced in abundance in response to an injury or stroke.
The researchers suggested the materials, described in the American Chemical Society journal ACS Applied Nano Materials, could aid treatment of COVID-19 patients.
The biocompatible, highly soluble charcoal is a superoxide dismutase, and was synthesized and tested by scientists at Rice University, the University of Texas Health Science Center’s McGovern Medical School and the Texas A&M Health Science Center.
Superoxide dismutases, or SODs, dismantle ROS into ordinary molecular oxygen and hydrogen peroxide. In the project co-led by Rice chemist James Tour, previous materials were successfully tested for their ability to activate the process, including graphene quantum dots drawn from coal and polyethylene glycol-hydrophilic carbon clusters made from carbon nanotubes.
They have now found oxidized charcoal nanoparticles are not only effective antioxidants but can also be made from an activated carbon source that is inexpensive, good manufacturing practice (GMP)-certified and already being used in humans to treat acute poisoning.
“That these nanozymes are made from a GMP source opens the door for drug manufacturers,” said Tour, who led the project with A&M neurologist Thomas Kent and UTHealth biochemist Ah-Lim Tsai. “While coal was effective, an issue is that it can have a variety of toxic metallic elements and impurities that are not consistent across samples. And the clusters made from carbon nanotubes are very expensive.”
The disclike nanozymes are prepared from powdered, medical-grade charcoal oxidized by treatment with highly concentrated nitric acid. The nanozymes teem with oxygen-containing functional groups that bust up superoxides in solution.
Tour noted the nanozymes are able to pass through the membranes of cells’ mitochondria to quench a major source of free radicals without killing the cells themselves. “We published a paperon this recently,” he said. “This seems to be really important to why these work so well in traumatic brain injury and stroke.”
“While speculative that these particles will be helpful in COVID-19, if administration is timed correctly, they could reduce the damaging radicals that accompany the cytokine storm and could be further chemically modified to reduce other injury-causing features of this disease,” Kent said.
Gang Wu, an assistant professor of hematology at McGovern, and Rice graduate student Emily McHugh are co-lead authors of the study. Co-authors are Vladimir Berka, a senior research scientist at McGovern; Rice graduate students Weiyin Chen, Zhe Wang and Jacob Beckham; Rice undergraduate Trenton Roy; and Paul Derry, an assistant professor at Texas A&M’s Institute of Biosciences and Technology.
Tour is the T.T. and W.F. Chao Chair in Chemistry as well as a professor of computer science and of materials science and nanoengineering at Rice. Kent is the Robert A. Welch Chair Professor in the Institute of Biosciences and Technology at Texas A&M-Houston Campus and an adjunct chemistry professor at Rice and at Houston Methodist Hospital. Tsai is a professor of hematology at UTHealth.
The National Institutes of Health and the Welch Foundation supported the research.
Artificial enzymes made of treated charcoal, seen in this atomic force microscope image, could have the power to curtail damaging levels of superoxides, toxic radical oxygen ions that appear at high concentrations after an injury. (Credit: Tour Group/Rice University)
Artificial enzymes made of charcoal nanoparticles heavily oxidized with fuming nitric acid (HNO3) could have the power to quench superoxides, toxic radical oxygen ions that appear at high concentrations in organisms after an injury. (Credit: Tour Group/Rice University)
Located on a 300-acre forested campus in Houston, Rice University is consistently ranked among the nation’s top 20 universities by U.S. News & World Report. Rice has highly respected schools of Architecture, Business, Continuing Studies, Engineering, Humanities, Music, Natural Sciences and Social Sciences and is home to the Baker Institute for Public Policy. With 3,962 undergraduates and 3,027 graduate students, Rice’s undergraduate student-to-faculty ratio is just under 6-to-1. Its residential college system builds close-knit communities and lifelong friendships, just one reason why Rice is ranked No. 1 for lots of race/class interaction and No. 4 for quality of life by the Princeton Review. Rice is also rated as a best value among private universities by Kiplinger’s Personal Finance.
Abnormal proteins in the gut could contribute to the development of Alzheimer’s Disease
UNDER STRICT EMBARGO UNTIL 01.00 GMT DAY 3 JULY 2020
Not for publication or broadcast before this time
A new study published inThe Journal of Physiology has shown that misfolded protein build-up in the gut could contribute to the development of Alzheimer’s-like symptoms in mice. This could suggest a new treatment approach for Alzheimer’s disease that would target the gut before symptoms of cognitive deficits appear in patients.
As these proteins were found in the gut, which is a window to the world, this suggests environmental factors might be contributing to cognitive deficits seen in Alzheimer’s disease and other conditions.
The misfolded protein, known to be involved in Alzheimer’s disease, called beta amyloid, was injected into the guts of mice and travelled to the “gut-brain" (the nervous system in our gut), and also to the brain.
If some of the beta amyloid build up in the central nervous system (brain and spinal cord) is originating from the outside the brain (peripheral nervous system), reducing the amount that makes it to the brain, or trapping the protein in the periphery may delay the onset of Alzheimer’s disease. This treatment would begin before any signs of dementia appear in the patient.
The researchers at The Chinese University of Hong Kong injected fluorescently-tagged beta-amyloid into the gut of mice. The proteins moved to the nervous system in our gut. The misfolded proteins were seen a year later in parts of the brain involved in cognitive deficits of Alzheimer’s disease including the hippocampus, the part of our brain that affects our memory. These animals experienced cognitive impairments.
As this study was conducted in mice, it needs verification by looking for post-mortem changes in inflammation in the gut and brain of patients with Alzheimer’s disease.
Development of drug treatments for Alzheimer’s disease has been unsuccessful so we instead need new approaches for preventing AD development. This could be a potential route for preventing the disease by targeting these misfolded proteins in the gut.
Commenting on the study, senior author John A Rudd said:
“This concept is similar to the transport of misfolded proteins from the gut such as those responsible for mad cow disease. If this is the case, a similar process may start in humans many years ahead of the manifestations of the classical hallmarks of AD including memory loss, and so prevention strategies would need to start earlier as well.”
The Journal of Physiology publishes advances in physiology which increase our understanding of how our bodies function in health and disease. http://jp.physoc.org
The Physiological Society brings together over 4,000 scientists from over 60 countries. The Society promotes physiology with the public and parliament alike. It supports physiologists by organising world-class conferences and offering grants for research and also publishes the latest developments in the field in its three leading scientific journals, The Journal of Physiology, Experimental Physiology and Physiological Reports. www.physoc.org
malgamation of Takeda Canada Inc. and Shire Pharma Canada ULC Solidifies Company's Leadership Position in Canadian Biopharmaceutical Industry
TORONTO, July 2, 2020 /CNW/ - Takeda Canada Inc. today announced the completion of the Canadian amalgamation with Shire Pharma Canada ULC, creating a portfolio of innovative treatments and establishing itself as a leader across several therapeutic areas.
Headquartered in Toronto with more than 350 employees across the country, the amalgamation marks the completion of the integration which began in January 2019. As a fully integrated company, Takeda Canada provides innovative medicines in the areas of Oncology, Rare Diseases, Gastroenterology, Neuroscience and Plasma-Derived Therapies, delivering highly-innovative medicines to Canadian patients.
"The transition to creating One Takeda in Canada couldn't have happened without the dedication and commitment of our employees who work tirelessly to ensure we leverage our collective strengths and expertise," said Gamze Yüceland, General Manager, Takeda Canada. "We're incredibly excited about the potential that bringing these two companies together creates, but even more importantly what it represents for Canadian patients."
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) ("Takeda") announced the completion of its acquisition of Shire plc ("Shire") in January 2019, becoming a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan. Takeda now has an attractive, expanded geographic footprint and leading position in Japan and the U.S., bringing its highly-innovative medicines to approximately 80 countries/regions with dedicated employees worldwide.
"The amalgamation in Canada is a significant milestone for Takeda in one of our key markets worldwide," said Giles Platford, President, Europe and Canada Business Unit. "I am confident that with this integration we will now be better positioned than ever to bring value to Canadian patients and healthcare providers."
About Takeda Canada Inc. Takeda Canada Inc. is the Canadian marketing and sales organization of Takeda Pharmaceutical Company Limited, headquartered in Japan. Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) is a global, values-based, R&D-driven biopharmaceutical leader committed to bringing Better Health and a Brighter Future to patients by translating science into highly-innovative medicines. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Gastroenterology (GI), Rare Diseases and Neuroscience. We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people's lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries and regions.
Additional information about Takeda Canada is available at www.takeda.com/en-ca.
SOURCE Takeda Canada Inc.
St. Jude-WHO Virology Expert Comments on Flu Season in the Southern Hemisphere, Potential of New Pandemic, & Testing for both COVID & the Flu
MEMPHIS, TENN. – As states see a spike in COVID positive cases, Dr. Richard Webby, a member of the Infectious Diseases Department at St. Jude Children’s Research Hospital and the World Health Organization’s Vaccine Composition Team, today commented on the current flu season in the Southern Hemisphere, a possible new pandemic with the swine flu, and testing for both COVID and the flu this fall.
On the current flu season in the Southern Hemisphere:
“So far, Australia and New Zealand are seeing very low rates of flu. And that’s due to the fact that what they’ve been doing to reduce the spread of COVID-19, with social distancing, wearing masks and disinfecting surfaces, works equally, if not better to prevent flu,” saidDr. Richard Webby, a member of the Infectious Diseases Department at St. Jude Children’s Research Hospital and the World Health Organization’s Vaccine Composition Team.
On the new swine flu:
“We’ve known about the threat of swine viruses in this group, so it’s not a new threat. But it does remind us of the potential threat of flu,” saidDr. Richard Webby, a member of the Infectious Diseases Department at St. Jude Children’s Research Hospital and the World Health Organization’s Vaccine Composition Team. “There are also other viruses that have similar properties that might make the jump into humans, but we can’t predict when that might happen. It could be tomorrow, it could be five years, 10 years or never.”
On testing for COVID and the flu:
“It is going to be critical to develop methods for simultaneously detecting influenza and COVID-19 infections,” saidDr. Richard Webby, a member of the Infectious Diseases Department atSt. Jude Children’s Research Hospitaland the World Health Organization’s Vaccine Composition Team. “The problem, of course, is the symptoms of COVID vs. influenza are very similar. And if these viruses continue to circulate, it’ll be a problem for providers determining who has flu and who has COVID. But the more critical point will be in what happens if you’re infected with both.”
Mitsubishi Tanabe Pharma Canada Announces that Manitoba has Added the Company's Treatment for Amyotrophic Lateral Sclerosis (ALS) to its Provincial Drug Formulary
TORONTO, June 30, 2020 /CNW/ - Mitsubishi Tanabe Pharma Canada, Inc. (MTP-CA), a subsidiary of Mitsubishi Tanabe Pharma America, Inc. (MTPA), announced today that RADICAVA® (edaravone), an infusion treatment for amyotrophic lateral sclerosis (ALS), has been added to the Manitoba Drug Benefits and Interchangeability Formulary (special authorization), and the listing will take effect on July 16.
"The listing of RADICAVA is encouraging news for the Manitoba ALS community," said Atsushi Fujimoto, President, MTP-CA. "We thank the Government of Manitoba for providing eligible ALS patients access to the therapy and their ongoing commitment to those affected by ALS."
MTP-CA continues to have discussions with other provinces, territories and federal agencies regarding the listing of RADICAVA under additional publicly funded drug programs. In addition to the Manitoba Drug Benefits and Interchangeability Formulary (special authorization), RADICAVA also is listed on the:
Régie de l'assurance maladie du Québec (RAMQ) formulary (special authorization);
Ontario Drug Benefit Formulary (Exceptional Access Program);
Alberta Drug Benefit List (special authorization); and
New Brunswick Drug Plan (NBDP) formulary (special authorization).
RADICAVA is an intravenous infusion treatment for ALS, a rapidly progressive, neurodegenerative and fatal disease.1
About RADICAVA® (edaravone)
RADICAVA (edaravone) is indicated to slow the loss of function in patients with amyotrophic lateral sclerosis (ALS), as measured by the ALS Functional Rating Scale - Revised (ALSFRS-R).2 Edaravone was discovered and developed for ALS by Mitsubishi Tanabe Pharma Corporation (MTPC) through an iterative clinical development platform over a 13-year period. In 2015, edaravone was approved for use as a treatment for ALS in Japan and South Korea. RADICAVA was approved by the U.S. Food and Drug Administration in May of 2017. Marketing authorization was granted in Canada in October 2018 and Switzerland in January 2019.
About Mitsubishi Tanabe Pharma Canada, Inc.
Based in Toronto, Mitsubishi Tanabe Pharma Canada, Inc. (MTP-CA) is a wholly-owned subsidiary of Mitsubishi Tanabe Pharma America, Inc. (MTPA) with a goal to provide therapies for some of the most difficult-to-treat diseases, including ALS. For more information, please visit
Based in Jersey City, N.J., Mitsubishi Tanabe Pharma America, Inc. (MTPA) is a wholly-owned subsidiary of Mitsubishi Tanabe Pharma Corporation's (MTPC) 100 percent owned U.S. holding company, Mitsubishi Tanabe Pharma Holdings America, Inc. MTPA is dedicated to delivering innovative products that address the unmet medical needs of patients in North America. It was established by MTPC to commercialize approved pharmaceutical products in North America with plans to expand its product line through collaborations with partners. For more information, please visit www.mt-pharma-america.com.
___________________________
1
National Institute of Neurological Disorders and Stroke. Amyotrophic Lateral Sclerosis (ALS) Information Page.
Discovery of new step in how brain cells work could lead to new therapies for epilepsy
Dublin, Tuesday, 30 June 2020: Researchers have identified a critical new step in how brain cells function in people with one of the most common forms of epilepsy. This could lead to new treatment approaches for people with drug-resistant epilepsy.
The study was led by researchers at FutureNeuro, the SFI Research Centre for Chronic and Rare Neurological Diseases, hosted by RCSI University of Medicine and Health Sciences with colleagues at Severo Ochoa-Centre for Molecular Biology (CBMSO) of Madrid and Institute for Research in Biomedicine (IRB) of Barcelona. The research is published in Brain.
Changes in gene activity are known to be important in the development of epilepsy. Normally, a molecule called messenger RNA is produced when a gene is active. This becomes the template for the production of the proteins that brain cells use to function. A critical step is the addition of a short sequence called a poly(A) tail. This has never been studied before in epilepsy. The team discovered that this tailing process (polyadenylation) is dramatically altered for about one third of the genes of someone with epilepsy, changing protein production in the brain.
“Our discovery adds another piece to the puzzle to help us understand why gene activity is different in someone with epilepsy,” said Dr Tobias Engel, FutureNeuro Investigator and Senior Lecturer in the School of Physiology and Medical Physics at RCSI. “It is remarkable that so many active genes in the brain show a change in this polyadenylation process. We believe that this could ultimately lead us to new targeted treatments, allowing us to investigate if we could stop a person from developing epilepsy.”
Epilepsy is one of the most common chronic brain diseases, affecting over 65 million people worldwide. While current drug treatments are usually effective in suppressing seizures, they do not work in one third of people with epilepsy and have no effect on the underlying causes of the disease.
“Regulated poly(A) tailing of messenger RNAs is a step in gene expression regulation barely explored in brain diseases, and our study should foster its investigation in other brain conditions in which gene expression alteration is suspected,” said Dr José Lucas, Research Professor at Severo Ochoa-Centre for Molecular Biology of Madrid.
Prof. David Henshall, Director of FutureNeuro and Professor of Physiology in the School of Physiology and Medical Physics at RCSI, said, “Our aim in FutureNeuro is to provide faster diagnostics, precision therapeutics and eHealth enabled solutions for those with chronic and rare neurological diseases. This research is a great example of how understanding basic mechanisms of a disease can guide us to new targets for treatment.”
This research was co-funded by the Health Research Board, H2020 Marie Skłodowska-Curie Actions Individual Fellowship and from the European Union’s Horizon 2020 research and innovation programme under the Marie Sklodowska-Curie grant agreement.
ENDS
About FutureNeuro
FutureNeuro is the SFI Research Centre for Chronic and Rare Neurological Diseases. We aim to change the patient journey through research informed by the needs of both patients and neurologists. This includes developing rapid and accurate tools for diagnosis, the development of therapies to correct damaged brain networks, technologies to enable patients to monitor their own health and well-being, and linking this to Ireland’s national imaging, diagnostics and eHealth infrastructure.
We are multi-disciplinary, inter-institutional and working with industry, patient organisations and the health service to transform the lives of patients in Ireland and worldwide.
About RCSI University of Medicine and Health Sciences
Ranked number one globally for Good Health and Well-being in the Times Higher Education (THE) University Impact Rankings 2020, RCSI University of Medicine and Health Sciences is an international not-for-profit university, with its headquarters in Dublin.
RCSI is exclusively focused on education and research to drive improvements in human health worldwide. It is among the top 250 universities worldwide in the THE World University Rankings (2020) and its research is ranked first in Ireland for citations. RCSI has been awarded Athena Swan Bronze accreditation for positive gender practice in higher education.
Visit the RCSI MyHealth Expert Directory to find the details of our experts across a range of healthcare issues and concerns. Recognising their responsibility to share their knowledge and discoveries to empower people with information that leads them to better health, these clinicians and researchers are willing to engage with the media in their area of expertise.
Safeguard Your Emotional Health During Any Crisis With These 7 Practical Steps
Boulder, CO, June 30, 2020 — In our interconnected world, global events impact all of us in one way or another. Knowing how to help ourselves, our families and our organizations navigate a crisis can profoundly affect our emotional health and well-being.
7 Keys to Navigating a Crisis: A Practical Guide to Emotionally Dealing with Pandemics & Other Disasters is a must-read for anyone seeking to thrive during challenging times. Written by clinical psychologist Elia Gourgouris and change management expert Konstantinos Apostolopoulos, this easy-to-read book offers powerful, yet practical, insights to help minimize the negative emotional impact of pandemics, natural disasters, financial challenges and other major disruptions.
“Not only will individuals and families find the book helpful in a crisis, so will first responders, healthcare professionals, mental health counselors and wellness coaches,” said Dr. Gourgouris.
Drawing from their real-world experiences, Dr. Gourgouris and Apostolopoulos explain the following seven keys to navigating any crisis:
1. Start with self-care. Be aware of your physical, mental, emotional and spiritual needs.
2. Practice awareness. Listen to your intuition or inner wisdom.
3. Choose flexibility so you can adapt, pivot and avoid unnecessary pain.
4. Act now! Preparation is key to your survival.
5. Take initiative by moving into action. Become the navigator in your life’s journey!
6. Cultivate a positive attitude filled with faith and hope.
7. Show kindness to others.
“Each chapter has an end section including points to ponder, questions to consider and action steps to take, so the reader can move beyond just surviving to thriving in a crisis situation,” added Apostolopoulos.
Author Elia Gourgouris, PhD, is the Founder of The Happiness Center, an organization of world-leading experts in the field of positive psychology. Dr. Elia's previous book, 7 Paths to Lasting Happiness, became an Amazon #1 best-seller. He is an international keynote speaker and happiness expert focusing on corporate wellness and leadership training. He holds a PhD in Clinical Psychology and is a UCLA graduate. Dr. Elia is certified by the American Red Cross in Disaster Mental Health Services, having assisted in the 1994 Los Angeles and 2010 Haiti earthquakes, the 1999 Columbine High School shooting and other crises. He's the co-host of The Kindness Happiness Connection podcast and a Thrive Global contributor. Please visit: https://www.linkedin.com/in/thehappinessdoctor/, https://www.instagram.com/dr.eliag/ or https://www.facebook.com/DrElia.
Co-author Konstantinos Apostolopoulos is the Founder and CEO of Fresh Biz Solutions, a performance consulting and training provider. As an award-winning facilitator and coach, he has successfully delivered hundreds of custom learning events in the US, Canada and Europe for diverse audiences and industries. He is a regular contributor to Thrive Global and other industry publications. As a young man in Greece, he experienced firsthand the devastation left behind by natural and economic disasters. As an adult, he was fortunate to help play a small part in the rebuilding efforts in New Orleans after Hurricane Katrina. Today, he helps others navigate the challenges brought by major events in their lives. Please visit: https://www.linkedin.com/in/coachkon/.
